GLOW studie

Titel: A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax
versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic
Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NB studie is gesloten per 15 januari 2019

• Protocol  (kwadraet)
• Patienteninformatie (kwadraet)

Studiemedicatie: Ibrutinib, Venoclax, Obinutuzumab & Chlorambucil

BEACONprotocol beschikbaar:  volgt

Verpleegkundige documenten:

Principal Investigator AMC: Arnon Kater

Studie coordinator: Roberto Liu

Aanmelden patienten via trialbureau hematologie (sein 59255, hemat.trial@amc.nl)